David West’s Post

GenomeWeb reports on Nucleai striking a deal to integrate its predictive biomarker technologies into Proscia cloud-based Concentriq digital pathology platform. This partnership will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions. #AI #spatialbiology #precisionmedicine #biomarker #diagnostics https://lnkd.in/e94gQQPe

Proscia and Nucleai Partner to Broaden AI Biomarker Access - DistilINFO Hospital IT Summary: Proscia and Nucleai have partnered to expand access to AI biomarkers in healthcare. This collaboration aims to enhance pathology workflows and improve patient outcomes. #ProsciaNucleaiPartnership Key Highlights: - Proscia and Nucleai join forces to leverage AI technology for biomarker analysis in pathology. #AItechnology #BiomarkerAnalysis - The partnership will streamline pathology workflows and provide more accurate diagnostic insights. #PathologyWorkflows #DiagnosticInsights - Healthcare professionals can expect improved efficiency and precision in biomarker identification and interpretation. #Efficiency #Precision - The collaboration will enable healthcare organizations to harness the power of AI for better patient care and treatment decisions. #PatientCare #TreatmentDec ai.mediformatica.com #proscia #nucleai #platform #hospital #partnership #medicine #pathology #precisionmedicine #this #collaboration #advanced #digital #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3XQKaMB)

PathAI, Roche to Develop AI-Enabled Digital Pathology Algorithms - HIT Consultant #PathAI and Roche Partner to Develop AI-Enabled Digital Pathology Algorithms #Summary: PathAI, a leading provider of artificial intelligence (AI)-powered pathology solutions, has announced a collaboration with Roche, a global pioneer in pharmaceuticals and diagnostics, to develop AI-enabled digital pathology algorithms. This partnership aims to enhance the accuracy and efficiency of cancer diagnosis and treatment. #Introduction: PathAI and Roche have joined forces to leverage AI technology and develop advanced algorithms for digital pathology. This collaboration aims to improve the accuracy and speed of cancer diagnosis, ultimately leading to more effective treatment options. #The Need for AI in Digital Pathology: Digital pathology involves the digitization of tissue samples for analysis, enabling pathologists to examine and diagnose ai.mediformatica.com #roche #diagnostics #pathai #algorithm #companion #pathology #algorithms #digital #digitalpathology #exclusive #this #collaboration #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3UXciMX)

What's all the hype about using exosomes in liquid biopsies? Check out AACR Journals 📰 to learn more about this promising new biomarker! Read> https://lnkd.in/gWWcCzJJ #healthcare #earlydetection #earlydetectionsaveslives #exosomes #exosomesresearch

AI image analysis apps in pathology aren't just experimental tools anymore. Several of them have received regulatory clearance both in the US and in Europe. Apps that quantify PR, PDL1, Ki67, and even assess lymph node metastasis have received the CE IVD mark, the regulatory approval for clinical use in Europe. Image analysis companies that don’t have an arsenal of approved apps and want to enter the clinical pathology market are not competitive anymore. It's not the future; it's the present and a requirement to help patients efficiently. It’s reshaping how we approach diagnostics and treatment planning. —----------------------------------------------------------------------- Curious to learn what’s AI's role in clinical trials? Listen to the full episode with MONIKA LAMBA SAINI Link to the full episode in the 1st comment below 🎙️ —----------------------------------------------------------------------- #AIinHealthcare #Pathology #ClinicalTrials

Curious about what AI apps are in use in pathology? In a podcast episode with MONIKA LAMBA SAINI we discuss what’s already out there and how it impacts diagnostics and clinical trials. Link to the full episode below 🎙️ #MedTwitter #PathTwitter #ClinicalTrials #ImageAnalysis

We're excited to announce our new partnership with iSpecimen, an online global marketplace that connects scientists with healthcare providers to access biospecimens! Through this collaboration, we'll be integrating our end-to-end AI-powered digital pathology and image management solutions into iSpecimen's platform. By leveraging TriMetis Computer-Assisted Pathology (TCAP) Ai, ARCH Marketplace, and ARCH LabFlow workflow automation capabilities together with iSpecimen's extensive network, we aim to significantly improve quality control, standardization, and enhanced data for tissue-based oncology samples. Researchers on iSpecimen's marketplace will be able to better select the most appropriate samples for their work. For suppliers, our solutions will increase efficiency in tissue sample reviews. This innovative partnership combines the strengths of our two specialized platforms to streamline and transform quality assessments, procurement, and accuracy for tissue sample research. We look forward to advancing cancer research together! https://lnkd.in/gMZmZKcW #Partnership #DigitalPathology #BioSpecimens #BioSpecimenMarketplace #Procurement #AI #ComputerAssistedPathology

Check out this upcoming webinar with Medidata Solutions to help optimize imaging strategies and support clinical trial outcomes! There will be discussions about implementing robust imaging workflows within data collection processes, enhancing efficiency and effectiveness in clinical trials, overcoming common imaging challenges, and streamlining imaging management. #ClinicalTrials #Oncology #ImagingData #AI #Medidata #Webinar #ClinicalResearch #MedicalImaging #ClinicalData #Diagnostics #SoftwareSolutions #DataSolutions #ClinicalTrialManagement #ClinicalOperations #DigitalHealth

🔬 **Exciting Partnership Alert!** 🔬 Alimentiv, AcelaBio, and PharmaNest are embarking on an extraordinary journey to revolutionize MASH (metabolic dysfunction-associated steatohepatitis) clinical trials through precision medicine and AI digital pathology solutions. This strategic alliance marks a significant leap forward in our collective efforts to address the complexities of metabolic liver diseases, particularly MASH, previously known as NASH. By integrating state-of-the-art spatial transcriptomics and AI-powered single-fiber and single-cell digital pathology, this collaboration empowers clinical trial sponsors to delve deeper into the histological effects and underlying mechanisms of MASH-targeted therapies. The seamless fusion of specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis creates an integrated ecosystem poised to drive scientific breakthroughs and accelerate drug development in MASH. **#PrecisionMedicine #DigitalPathology #AI #ClinicalTrials #MASH #NASH #DrugDevelopment #HealthcareInnovation #MedicalResearch #Bioinformatics #ArtificialIntelligence #PathologyInsights #Biomarkers** Niels Vande Casteele, Ph.D., President of AcelaBio, expressed, "Our collaboration holds great potential for advancing MASH clinical research, unlocking new opportunities to identify biomarker signatures within the tissue's spatial context." Wendy Teft, Ph.D., VP of Precision Medicine at Alimentiv, stated, "Through the integration of our technologies and expertise, we aim to empower clinical trial sponsors to enhance histological endpoints, uncover novel biomarkers, and expedite drug development timelines." Mathieu Petitjean, Ph.D., CEO of PharmaNest, added, "Our partnership ensures sponsors receive a superb end-to-end digital pathology tissue assay, bolstering early drug development efficiency." Synergy Healthcare applauds this alliance and eagerly anticipates opportunities to contribute to MASH research alongside these esteemed partners. Together, we're committed to advancing patient outcomes and driving innovation in the development of personalized therapies for MASH. **#Collaboration #HealthTech #ClinicalInnovation #MedicalScience #ResearchPartnership #HealthTech #DrugDiscovery #InnovativeSolutions #HealthcareCollaboration #PatientCare #MedicalBreakthroughs** 🔗 https://lnkd.in/dbjWCaBV

PathAI, a global leader in AI-powered pathology, today announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology (AP) labs accelerate the adoption of AI and digital pathology. PathAI’s AISight Intelligent Image Management System (IMS) is an AI-native IMS that seamlessly blends PathAI and third-party algorithms into a single laboratory workflow and image analysis platform, providing researchers and pathologists direct access to powerful biomarker quantification tools that have the potential to increase lab operational efficiency and aid in disease staging and scoring. PathAI will leverage Google Cloud’s infrastructure to bring AISight to more biopharma companies and AP labs worldwide, enabling faster deployments of novel AI models for a variety of clinical and research needs. #digitalpathology #pathologynews